The effect of compound honey syrup on the airways of cystic fibrosis patients Fractional exhalation Nitric Oxide

Phase 3

Recruiting

• Conditions: Cystic fibrosis.; Cystic fibrosis

• Registration Number: IRCT20200428047229N2
• Lead Sponsor: Shahid Beheshti University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 17 August 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

All cystic fibrosis patients over 6 years of age should be referred to the pulmonary clinic of Mofid Children's Hospital, diagnosed by a pediatric lung specialist.
Conscious consent of parents of children and children over 6 years of age

Exclusion Criteria

Cystic fibrosis patients under 6 years of age referred to the pulmonary clinic of Mofid Children's Hospital
Patients in need of hospitalization
Patients who have attack symptoms of the disease (increased cough, sputum, fever, and need for hospitalization).
Patients with underlying diseases such as allergic bronchopulmonary aspergillosis, heart failure and tuberculosis.
Patients with other acute illnesses during treatment.
Patients who are allergic to any of the components of the compound honey syrup.
Patients who have decided to leave the study at their own request.
Patients who are unable to co-operate with the FeNO test.

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Fractional exhalation Nitric Oxide. Timepoint: At the beginning of the study (before the start of the intervention) and the twelfth week after the start of the compound honey syrup. Method of measurement: FeNO monitor (NObreath®).